

Agenda

- NIH Notice on Sequestration
- Impact of Continuing Resolution on UMMS NIH Funding
- Proposal Routing Form Overview
- SDFI Form Overview
- Revised Annual Progress Report Form
- Revised Proposal Approvals/Signature Checklist Form
- Research Performance Progress Report (RPPR) Training
- Updated Proposal & Progress Report Statistics



NIH Operation Plan in the Event of a Sequestration

Notice Number: NOT-OD-13-043

Key Dates Release Date: February 21, 2013

Related Announcements:

NOT-OD-13-002

Issued by

National Institutes of Health (NIH)

Purpose

The NIH continues to operate under a Continuing Resolution as described in NOT-OD-13-002, and therefore all non-competing continuation awards are currently being funded at a level below that indicated on the most recent Notice of Award (generally up to 90% of the previously committed level). Final levels of FY 2013 funding may be reduced by a sequestration. Despite the potential for reduced funding, the NIH remains committed to our mission to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability.

Should a sequestration occur, NIH likely will reduce the final FY 2013 funding levels of non-competing continuation grants and expects to make fewer competing awards to allow the agency to meet the available budget allocation. Although each NIH Institute and Center (IC) will assess allocations within their portfolio to maximize the scientific impact, non-competing continuation awards that have already been made may be restored above the current level as described in NOT-OD-13-002 but likely will not reach the full FY 2013 commitment level described in the Notice of Award. Finally, in the event of a sequestration, NIH ICs will announce their respective approaches to meeting the new budget level


Inquiries


Questions regarding adjustments applied to individual grant awards may be directed to the Grants Management Specialist identified on the Notice of


Impact of Current Continuing Resolution on UMMS NIH Funding


- Since October 12, 2012 UMMS has received 31 non-competing awards at a level below that indicated on the most current notice of award
- Cumulative downward adjustment:
 - \$2,820,804
- NIH will consider upward adjustments if/when FY13 appropriations are enacted.











 Section I (Award Information) 	Annual Progress Report Form This form is required for RFS review and approval of Progress Reports on established projects.							
Revised to include Submission Type Box	Ensured Contact Native Physics Empli	Requested Return Date						
Type box	L AWARD INFORMATION							
RPPR added as a choiceSNAP remainsPaper submission added as a	Award Tips Federal Flow Through ("Yes ("No Type: Confinuation Control Name) Sponsor Name Sponsor Red. Award II: På Award III	OTHER						
choice	II. PRINCIPAL INVESTIGATOR INFORMATION	red by aponaur? (Yes (N						
21	Current Effort %. Will the level of effort for the Princip	l Investigator C Yes C No.						
 Other type added for non-NIH sponsors 	PI Name Change significantly (25% or more) is budget partial? Pi Phone budget partial? Opt. Name Project Location (if shanged)	the next						
•	III. CO-INVESTIGATORS							
 Section IV (Next Period Budget 	Name Department Sometime (See Section							
& Subrecipients) — Reminder to use the Direct,	Name Digadment Signature (Des Octobre	one (in Sec. VIII) for UMMS PaulProf II						
 Reminder to use the Direct, 		ens (H. Déc. VIII) for UMMS Pau/Pool D						
 Reminder to use the Direct, Indirect and Total Costs committed 	NV. NEXT PERIOD BUDGET & SURRICIPIENTS Blad Date End D							
 Reminder to use the Direct, Indirect and Total Costs committed in the sponsor's previous year 	IV. NEXT PERIOD BUDGET à SUBRECIPIENTS Start Culte End Date IV. NEXT PERIOD BUDGET à SUBRECIPIENTS	NEXT PERIOD BUDG						
 Reminder to use the Direct, Indirect and Total Costs committed 	IV. NEXT PERIOD BUDGET & SUBRECIPIENTS LECAL NAME OF SUBSCIPIENT							
 Reminder to use the Direct, Indirect and Total Costs committed in the sponsor's previous year 	IV. NEXT PERIOD BUDGET & SUBRECIPIENTS Start Date Find Date ICOAL HAME OF SUBRECIPIENT Version additional size of recessary) Direct Coals Indirect Coals Total Coals One Amounts from most recent Notice of Oxerf Award (NOA)							
 Reminder to use the Direct, Indirect and Total Costs committed in the sponsor's previous year 	IV. NEXT PERIOD BUDGET A SUBRECIPIENTS Blad Date End Date End Date Direct Coats Indirect Coats	NEXT PERIOD BUDG						
 Reminder to use the Direct, Indirect and Total Costs committed in the sponsor's previous year 	IV. NEXT PERIOD BUDGET & SUBRECIPIENTS Start Date Find Date ICOAL HAME OF SUBRECIPIENT Version additional size of recessary) Direct Coals Indirect Coals Total Coals One Amounts from most recent Notice of Oxerf Award (NOA)	NEXT PERIOD SUD						

Revised Proposal nature Checklist Approvals/Signature Date: Contact E-Mail: Checklist Form 'Department Administrator' added to list of signatures DATE RECEIVED DATE RECEIVED required for grant submission review □ ___ _ _ DATE RECEIVED o ___

Research Performance Progress Report Training

- Scheduled for Wednesday, 2/27/13
 - Hiatt Auditorium S1-608
- Use of RPPR submission method mandated effective April 2013
- Replaces eSNAP Progress Reports
- Not available for Complex Awards and Training Grants
- Additional information at: http://grants.nih.gov/grants/rppr/
- We strongly encourage your attendance. No registration is required



PROPOSALS	January 2012	February 2012	March 2012	April 2012	May 2012	June 2012	July 2012	August 2012	September 2012	October 2012	November 2012	December 2012	January 2013
Count	136	119	95	61	104	100	84	62	100	125	75	75	139
On Time	60%	61%	45%	33%	51%	50%	50%	60%	62%	50%	41%	43%	52%
Late	36%	33%	48%	57%	40%	43%	48%	35%	37%	48%	49%	48%	47%
After the fact	4%	6%	7%	10%	9%	7%	2%	5%	1%	2%	9%	9%	1%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Expedited Request (3 days or less)	24%	23%	35%	39%	31%	31%	29%	26%	22%	31%	29%	35%	32%
On Time: Received by RFS 5 days prior to the requested return date. Late: Received by RFS less than 5 days prior to the requested return date. After the Fact: Received by RFS after the requested return date. Expedited Request: Received by RFS with 3 days or less to review before requested return date. University of Massachusetts Medical School													

SUBMISSIONS TO RFS January 2012 to January 2013 Comparison Change 2012 2013 **PROPOSALS** Count 136 139 +3 On Time 60% -8% 52% Late 36% 47% +11% After the fact 4% 1% -3% Total 100% 100%

24%

32%

On Time: Received by RFS 5 days prior to the requested return date.

Late: Received by RFS less than 5 days prior to the requested return date.

After the Fact: Received by RFS after the requested return date.

Expedited Request: Received by RFS with 3 days or less to review before requested return date.

Expedited Request (3 days or less)



+8%

January 2012 February 2012 April 2012 August 2012 August 2012 September 2012 October 2012 November 2013 January 2013													
Count	34	41	40	45	39	29	26	10	11	23	22	20	25
On Time	50%	41%	45%	47%	34%	38%	23%	30%	37%	26%	27%	55%	40%
Late	47%	49%	38%	42%	56%	41%	62%	50%	27%	43%	41%	25%	48%
After the fact	3%	10%	17%	11%	10%	21%	15%	20%	36%	30%	32%	20%	12%
Total	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%
Expedited Request (3 days or less)	44%	41%	30%	29%	31%	17%	31%	30%	0%	35%	36%	10%	44%
On Time: Received by RFS 5 days prior to the requested return date. Late: Received by RFS less than 5 days prior to the requested return date. After the Fact: Received by RFS after the requested return date. Expedited Request: Received by RFS with 3 days or less to review before requested return date.													

SUBMISSIONS TO RFS January 2012 to January 2013 Comparison

PROGRESS REPORTS	2012	2013	Change
Count	34	25	-9
On Time	50%	40%	-10%
Late	47%	48%	+1%
After the fact	3%	12%	+9%
Total	100%	100%	-
Expedited Request (3 days or less)	44%	44%	0%

On Time: Received by RFS 5 days prior to the requested return date.

Late: Received by RFS less than 5 days prior to the requested return date.

After the Fact: Received by RFS after the requested return date.

Expedited Request: Received by RFS with 3 days or less to review before requested return date.



Report ID: UMGM7002 Environment: Production Page No: 1

Run Date: 01/17/2013 Run Time: 11:51:03 AM

Proposal No. 000000000015033 Status: STSR - Submit to Sponsor

I. Principal Investigator Information

PI Name: Investigator, Principal Alt. Name Wonderland, Alison Department: W416800000 - Aches & Pains Alt. Phone 508/856-4063

Alt. Email PI Phone: alison.wonderland@umassmed.edu

PI Email: Requested Return Date: 02/04/2013

II. Proposal Information

New CFDA#: 12,190 Type: Additional Attribute: GRANT Foreign Component:

Purpose: BASIC Proposal Title: Vectored Delivery of Oligoclonal Antibodies for Protection Against EMDD

NATIONAL INSTITUTES OF HEALTH Foreign

Sponsor:

Proposed Period Start Date: 09/01/2013 Proposed Period End Date: 08/31/2018 MEDICAL SCHOOL Proposal Location:

Date Due to Sponsor: 02/05/2013 Due By:

Time: Keywords:

Adequate Space Available:

III. Subawardees/Subrecipients

F-Y/N 1st Yr Budget Total Budget Name:

BOSTON UNIVERSITY 99,927.00 539,710.00 UNIVERSITY OF MARYLAND 663,144.00 147,691.00

IV. Proposal Budget

Initial Budget Period Start Date: 09/01/2013 Initial Budget Period End Date: 08/31/2014

			Indirect Cost	Total Budget	
1st Period Budget	\$	3,465,734.00	\$ 281,747.00	\$	3,747,481.00
2nd Period Budget	\$	3,171,497.00	\$ 672,294.00	\$	3,843,791.00
3rd Period Budget	\$	3,481,442.00	\$ 671,645.00	\$	4,153,087.00
4th Period Budget	\$	2,574,846.00	\$ 402,572.00	\$	2,977,418.00
5th Period Budget	\$	457,275.00	\$ 6,500.00	\$	463,775.00

\$ 2,034,758.00 Total Budget-Project \$ 13,150,794.00 \$ 15,185,552.00 Does Proposal Involve Cost Sharing? N

Does Sponsor Require Cost Sharing? Ν Does Sponsor Limit Indirect Costs? N

Has an Indirect Cost Waiver been Requested? $\ensuremath{\mathbb{N}}$

H001

HUMAN SUBJECTS

Are InKind/Voluntary Costs Included?

V. Co-Investigators

Department: Signature (UMASS Staff only) Name:

Gao, Guangping Gene Therapy Center

VI. Certifications

NO

Cert. Code/Description Indicator Docket/Protocol# Approval Date

A025 ANIMAL PD Report ID: UMGM7002 Environment: Production

UNIVERSITY OF MASSACHUSETTS PROPOSAL ROUTING FORM

Page No: 2 Run Date: 01/17/2013 Run Time: 11:51:03 AM

Proposal No. 00000000015033 Status: STSR - Submit to Sponsor

VII. Declarations & Department Approvals

Signature of the Principal Investigator below (and Co-Investigators in Section V) indicates:

- * assurance that the information submitted within the application is true, complete and accurate to the best of the PI`s knowledge
- * certification that they are not currently suspended, debarred, or proposed for debarment or suspension for doing business with the Federal Government.
- * compliance of the proposal with applicable, institution, sponsor, federal, and state rules, regulations and guidelines,
- * acceptance of the responsibility to conduct and judiciously manage the project in accordance with the terms and conditions of the sponsoring agency and the institution in the event that this proposal is funded and accepted by the University,
- * UMASS resources necessary to complete the project are available or provisions have been arranged with the appropriate personnel to make such
 - resources available in the event that this proposal is funded,
- * assurance that they are in compliance with the Institutions` Patent Policy and Conflict of Interest Policy.

Signature of the Department Administrator (as required) below indicates:

* assurance of departmental review of the proposal information and budget for accuracy and compliance with sponsor and institution guidelines.

Signature of the Department Chair(s) (as required) below indicates:

- * approval of project and confirmation that appropriate space and facilities are available to meet the proposed goals,
- * cognizance of the proposed project`s risks and administrative obligations,
- \star acceptance of the obligation of Department funds to meet any cost sharing proposed in this project.

Principal Investigator	Additional Department Chair/Division Chief (as Required)
Department Administrator (as Required)	Additional Department Chair/Division Chief (as Required)
Department Chair (as Required)	Additional Department Chair/Division Chief (as Required)
7	VIII. Institution Approvals
Dean/Provost (as Required)	Chancellor (as Required)
Dean/Provost (as Required)	Special Approval (as Required)

Authorized Institutional Official - Grants & Contracts/Research Funding/ Sponsored Projects Office



University of Massachusetts Medical School

Proposal ID# or Sponsor Award ID:	
1	

Collaborators

Others w/SFIs

Summary Disclosure of Financial Interests Completion of this form is mandatory for all proposals. This information is required to comply with the University of Massachusetts Medical School Policy for Promoting Objectivity in Biomedical Research and applicable federal and state laws and regulations regarding timely and proper disclosure of financial interests. Principal Investigator Title: Principal Investigator Name: Last, First, MI Department: Sponsor: Project Start Date: Project End Date: Project Title: The Project Principal Investigator is responsible for determining who meets the definition of an "Investigator" on their project and certifies that this form provides: a complete disclosure of all Investigators responsible for the design, conduct, or reporting of activities associated with this project, and 2. an accurate report of the current state of the named Investigator's disclosure in the institution's electronic reporting system. Principal Investigator agrees to update the UMMS COI system annually during the period of the award and within 30 days of discovering or acquiring a new Significant Financial Interest. Principal Investigator Disclosure & Certification Do you, your spouse/domestic partner or dependent children have any Significant Financial Interests (SFI) related to the Investigator's Institutional Responsibilities? Please answer below. (Reference definitions on the reverse side of this form). Yes No If yes, investigator confirms the disclosure on the UMMS COI System (http://coi.umassmemorial.org/coi/) has been updated and is current. Signature of Principal Investigator Date Disclosures & Certifications for UMass Personnel Identified as "Investigators" For the purposes of this disclosure, <u>Investigator</u> is defined as any person, <u>regardless of title or position</u>, who is responsible for the design, conduct, or reporting of research, or proposed for such funding, which includes subawardees and may include consultants and unpaid collaborators. By signing below each Investigator (1) certifies that this form provides an accurate report of whether there are any Significant Financial Interests related to their Institutional Responsibilities, and (2) acknowledges responsibility to provide a complete disclosure of all Significant Financial Interests reasonably related to their Institutional Responsibilities prior to award receipt, as those interests change, and on an annual basis during the project award period. Institutional Responsibilities means an Investigator's professional responsibilities on behalf of the Institution, including activities such as research, teaching, clinical or other professional practice, academic activities, scholarly events, institutional committee memberships, and service on panels such as Institutional Review Boards or Data and Safety Monitoring Boards. Do you, your spouse/domestic partner or dependent children have any Significant Financial Interests (SFI) related to the Investigator's Institutional Responsibilities? Please answer below. (Reference definitions on the reverse side of this form). 1. Yes No If yes, investigator confirms the disclosure on the UMMS COI System (http://coi.umassmemorial.org/coi/) has been updated and is current. Disclosing Investigator: Title: Signature Date 2. Yes No If yes, investigator confirms the disclosure on the UMMS COI System (http://coi.umassmemorial.org/coi/) has been updated and is current. Disclosing Investigator: Title: Signature Date Yes No If yes, investigator confirms the disclosure on the UMMS COI System (http://coi.umassmemorial.org/coi/) has been updated and is current. Disclosing Investigator: Title: Signature Date If yes, investigator confirms the disclosure on the UMMS COI System (http://coi.umassmemorial.org/coi/) has been updated and is current. Disclosing Investigator: Title: Date Signature (Check here if additional investigator disclosures are being submitted on the Additional Signatures Page) Yes No Will Non-University Investigators be responsible with the PI or Co-PI for the design, conduct, or reporting of the activities associated with the project (e.g., subrecipients, consultants, collaborators, others with significant responsibilities)? If yes, UMMS must be assured that the Investigators' home institution(s) have policies that comply with the sponsor's regulations. Such assurance should be provided along with the participant's Letter of Intent/Commitment to the project at the submission stage.

If yes, please identify non-University Investigator type (check all that apply): Subrecipients Consultants

University of Massachusetts Medical School Annual Progress Report Form

This form is required for RFS review and approval of Progress Reports on established projects.

Document Contact	Name	Phone		Email		Requested Return Date						
I. AWARD INFORMATION												
Award Title Award Type Sponsor Name Sponsor Ref. Av PS Award #:	vard #:	Federal Flow-Thro		○ No	Type: Continuation Date Due to Sponsor	SUBMISSION TYPE RPPR						
		II. PRINCIPAL IN	IVESTIGAT			y spansa : Tes Tio						
PI Name PI Phone		Current Eff	bu	ange significa idget period?	antly (25% or more) in the	vestigator Yes No next						
Dept. Name		500 1 2 2	D-INVESTIG	oject Location	(ii changeu).							
Name	Must be UMMS	Faculty or Professional S Department	taff unless a S		ubrecipient is indicated belo gnature (See Declarations (w. in Sec. VIII) for UMMS Fac/Prof Staff)						
		IV. NEXT PERIO	D BUDGET	& SUBRECIF	PIENTS							
Start Date Direct Costs	End Date Indirect Costs	Total Costs		AME OF SUBR ditional sites if		NEXT PERIOD BUDGET \$ \$ \$ \$						
Use amounts from	most recent Notice of Gr					Ψ						
Daga Auszard In al. 1	Coat Sharing C V	2760N	COST SHA	201-027-027-027-04								
Does Award Include	Cost Sharing? (Yes	No If yes, ide		I attach docum	The second secon	equired In Kind/Voluntary						
If yes, the Departme provisional account. referenced below wi		blishment of a provisional APR Form. RFS will subn d, or expenditures process e for these expenses:	account? nit a copy of th	Yes C	No approved APR form to Grar	nt Accounting to set up the of the award, the PS ST# account						

For awards that will require multiple projects for the year please attach a listing of the number of projects needed, the title of the project(s), the project investigator(s) and the department ID(s).

			VII.	DISCLOSURE OF I	FINANCIAL INTEREST UPDATE						
			₹) form with the APR packet. All			FOR F	RFS USE ONL	Y Ye	s No
who is responsible for	or the	desig	gn, conduct or report	ing of research, o	regardless of title or position, or proposed for such funding)			SDFI F	orm Submitted	? (0
are required to provide institutional review and	before RFS can auth			Affirmati	ve Disclosures	? C	0				
RFS will also confirm to before the next segment			Ŋ	nvestig	jator Trair	ning Confirmed	? C	0			
			VIII.	COMPLIANCE INI	FORMATION/CERTIFICATIONS	3.					
	Yes	No	Docket/Protocol#	Approval Date				Ę	Yes No		
Human Subjects?	0	\bigcirc	D G S (C) T G (G G G)	Approval Bate	Has the involvement of human	cubic	otc ob	on god?	0 0		
Animal Subjects?	Ö	$\tilde{\circ}$			Has the involvement of animal			1770	00		
Allinai Gabjects:		\sim			rias the involvement of animal	Jubje	ots on	ungeu:			
	Yes	No		Yes No							
Inventions?	\circ	\circ	Previously Reported?	00							
Indicate below the ap	propr	iate a	ctivities involved in t	his project. Please	e list the valid IBC Protocols the	at co	ver thi	s activity	(-s		
	Yes	No	Docket/Protocol#	Approval Date		Yes	No	Docket	Protocol#	Approva	I Date
Radioactive Materials	\circ	\circ			Blood - Animal	\circ	0				
Recombinant DNA	\circ	\circ			Blood - Human	\circ	\circ				
Adult Stem Cells	\circ	\circ			Tissue - Animal	\circ	\circ				
Embryonic Stem Cells	\circ	\circ			Tissue - Human	\circ	\circ				
Select Agent	\circ	\circ			Microbial Pathogen-Animal		0				
Biologic Toxin	\circ	\circ			Microbial Pathogen-Human		0		1		
Pathogen - Animal	\bigcirc	\circ			Cell Lines - Animal		0		-		
Pathogen - Human	\circ	$\tilde{\circ}$			Cell Lines - Human	$\tilde{\circ}$	Ö				
_											
			IX. DE	ECLARATIONS 8	DEPARTMENT APPROVAL	_S					
* Assurance that * Certification tha * Compliance of t * Acceptance of t agency and the * UMMS resource * Assurance they Signature of the Dep * Assurance of de Assurance of the Dep * Approval of proj * Cognizance of t * Acceptance of t	the infat they the aw the res institutes neces are in coartment of artmeters are the protection of the	formal are no ard w ponsition. essar compent Ac nental nental d con ject's igation	ot currently suspended ith applicable, institution bility to continue to constitute to constitute to complete the projection of the information of the information of Department funds and administrative of Department funds	e report (if applicabe, debarred, or proport, sponsor, federal, duct and judiciously tet will continue to be ions' Intellectual Proportion and budget for a con and budget for a courate and utilow indicates; ate space and facilities obligations, to meet any cost sh	le) is true, complete and accurate psed for debarment or suspension and state rules, regulations and y manage the project in accordance available for the project. Superty Policy and have provided use couracy and compliance with spoundated protocol information for the sies are available to continue to make the provided of the same available to continue to make the same the	n for c guide ce wi pdate onsor nis pro	loing b lines, th the t ed COI and ins oject.	usiness we erms and disclosur stitution g	vith the Federa I conditions of the session of the ses	he spons	oring
Principal Investigator Additional Department Chair/Division Chief (as Required)									 8		
Department Adminis	strator				Additional Department	nt Chai	r/Divisior	n Chief (as R	equired)		
Department Chair					Additional Departme	nt Chai	r/Divisior	n Chief (as R	equired)		
				X. INSTITU	TION APPROVALS						

Special Approval (as Required)

Authorized Institutional Official - Office of Research Funding Services

				Proposal ID#	1	
	Proposal	l Approva	als - Signature (Checklist	12 1	
Principal Investigator:			Date:			
Department Contact:			Contact E-Mail:			
Contact Phone:						
5	Signatures Re	eauired f	or Grant Submi	ssion Review		
Check the box for all si	gnatures that hav	e been secur				een secured.
C	Summary Discl of Financial Intere		ļ	Proposal Routing Form		
	(SDFI)	DATE	RECEIVED	(PRF)	DATE RI	ECEIVED
		COPY	ORIGINAL	C	OPY	ORIGINAL
Principal Investigator		d <u>eli</u>	<u> </u>			<u> </u>
Co-Investigator (list below)					
1.		<u></u>			<u>-</u>	
2.		<u>12:</u>	<u> </u>			
3.					₹2	
4.						
5.		AC-				
Individuals identified by the Pl	 I that meet the F	COI policy	y Investigator* defir	nition are required	d to discl	ose on the SDFI.
* Investigator is defined as any			· · · · · · · · · · · · · · · · · · ·			
1.		<u>v. </u>				
2.						
3.		No.				
4.		ri .				
5.					DATE RI	ECEIVED
				C	OPY	ORIGINAL
PI's Chair / Department A	dministrator					
Additional Chairs for Co-I	nvestigators & (Other Key I	Personnel			
1						
2.						
3.						